Prospective clinical trials using pharmacologic and/or nutritional interventions that can modulate circulating FGF19 and FGF21 levels could help elucidate further the exact roles of these two hormones in the pathophysiology of diabetes. Here, FGF19 is linked to diabetes mellitus.